Given that the protective effect of genetic deletion or depletion of PARP2 in psoriasiform inflammation may probably be boiled down to increased estradiol synthesis of keratinocytes, our data might raise the potential of repurposing PARP inhibitors in the treatment of psoriasis. The gene discussed is PARP2; the disease is psoriasis.